| Thomas Page, DO | |
|
155 Center St Bldg F, Auburn, ME 04210-5229 | |
| (207) 241-0754 | |
| Not Available |
| Full Name | Thomas Page |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 155 Center St Bldg F, Auburn, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174503155 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 1511 (Maine) | Primary |
| Entity Name | Bridgton Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154370153 PECOS PAC ID: 8123919099 Enrollment ID: O20040322000534 |
News Archive
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
"India's drug industry — on track to grow about 13 percent this year, to just over $24 billion — was once notorious for making cheap knockoffs of Western medicines and selling them in developing countries. But India, seasoned in the basics of medicine making, is now starting to take on a more mainstream role in the global drug industry, as a result of recent strengthening of patent law here and cost pressures on name-brand drug makers in the West," the New York Times writes.
Using advanced mass spectrometry technology, scientists from the Florida campus of The Scripps Research Institute have developed a molecular model that may provide a new framework for improving the design of osteoporosis treatments.
Alternative splicing of obesity and type 2 diabetes related genes may contribute to the pathophysiology of obesity, according to research from the University of Eastern Finland. Obesity leads to changes in the splicing pattern of metabolically relevant genes such as TCF7L2 and INSR, resulting in impaired insulin action.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
› Verified 7 days ago
| Entity Name | Central Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689653487 PECOS PAC ID: 2567379563 Enrollment ID: O20040324000441 |
News Archive
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
"India's drug industry — on track to grow about 13 percent this year, to just over $24 billion — was once notorious for making cheap knockoffs of Western medicines and selling them in developing countries. But India, seasoned in the basics of medicine making, is now starting to take on a more mainstream role in the global drug industry, as a result of recent strengthening of patent law here and cost pressures on name-brand drug makers in the West," the New York Times writes.
Using advanced mass spectrometry technology, scientists from the Florida campus of The Scripps Research Institute have developed a molecular model that may provide a new framework for improving the design of osteoporosis treatments.
Alternative splicing of obesity and type 2 diabetes related genes may contribute to the pathophysiology of obesity, according to research from the University of Eastern Finland. Obesity leads to changes in the splicing pattern of metabolically relevant genes such as TCF7L2 and INSR, resulting in impaired insulin action.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
› Verified 7 days ago
| Entity Name | Rumford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205991122 PECOS PAC ID: 3870583511 Enrollment ID: O20040514000890 |
News Archive
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
"India's drug industry — on track to grow about 13 percent this year, to just over $24 billion — was once notorious for making cheap knockoffs of Western medicines and selling them in developing countries. But India, seasoned in the basics of medicine making, is now starting to take on a more mainstream role in the global drug industry, as a result of recent strengthening of patent law here and cost pressures on name-brand drug makers in the West," the New York Times writes.
Using advanced mass spectrometry technology, scientists from the Florida campus of The Scripps Research Institute have developed a molecular model that may provide a new framework for improving the design of osteoporosis treatments.
Alternative splicing of obesity and type 2 diabetes related genes may contribute to the pathophysiology of obesity, according to research from the University of Eastern Finland. Obesity leads to changes in the splicing pattern of metabolically relevant genes such as TCF7L2 and INSR, resulting in impaired insulin action.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Page, DO 155 Center St Bldg F, Auburn, ME 04210-5229 Ph: (207) 241-0754 | Thomas Page, DO 155 Center St Bldg F, Auburn, ME 04210-5229 Ph: (207) 241-0754 |
News Archive
Until human genes are activated, they are blocked by structures known as nucleosomes, components that serve to package DNA inside cells.
"India's drug industry — on track to grow about 13 percent this year, to just over $24 billion — was once notorious for making cheap knockoffs of Western medicines and selling them in developing countries. But India, seasoned in the basics of medicine making, is now starting to take on a more mainstream role in the global drug industry, as a result of recent strengthening of patent law here and cost pressures on name-brand drug makers in the West," the New York Times writes.
Using advanced mass spectrometry technology, scientists from the Florida campus of The Scripps Research Institute have developed a molecular model that may provide a new framework for improving the design of osteoporosis treatments.
Alternative splicing of obesity and type 2 diabetes related genes may contribute to the pathophysiology of obesity, according to research from the University of Eastern Finland. Obesity leads to changes in the splicing pattern of metabolically relevant genes such as TCF7L2 and INSR, resulting in impaired insulin action.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
› Verified 7 days ago